论文部分内容阅读
目的:观察阿罗格尘螨疫苗治疗变应性鼻炎的疗效及安全性。方法:回顾分析32例接受特异性免疫治疗的患者资料,观察治疗后临床疗效及不良反应发生率。结果:32例患者治疗后的症状、体征积分较治疗前均明显减少(P<0.01)。总计免疫治疗注射1 920次,局部反应的发生率为15.6%(299/1 920),全身反应的发生率为0.16%(3/1 920),未出现致命性全身反应。结论:特异性免疫治疗是一种安全、有效的治疗方法。
Objective: To observe the efficacy and safety of Arroge dust mite vaccine in the treatment of allergic rhinitis. Methods: The data of 32 patients receiving specific immunotherapy were retrospectively analyzed. The clinical efficacy and the incidence of adverse reactions after treatment were observed. Results: The scores of symptoms and signs of 32 patients after treatment were significantly lower than those before treatment (P <0.01). A total of 1 920 immunotherapy injections occurred, with a local response rate of 15.6% (299/1 920) and a systemic response rate of 0.16% (3/1 920) with no lethal systemic response. Conclusion: Specific immunotherapy is a safe and effective treatment.